Methods and compositions for maintaining nutrition and removing waste products in tissue injuries and wounds
Patent Information
- Application Number
- JP2023551648
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-10-28
- Filing Date
- 2021-10-27
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Tissue injuries and surgeries, particularly in immunoprivileged and poorly vascularized areas, face challenges in healing due to insufficient local tissue homeostasis and regenerative support, leading to incomplete healing rates and graft survival issues.
The use of nutritional support substances, such as a slow elution carrier with a nutrient cocktail, and waste removal agents, delivered via implantable or injectable microparticles, to enhance cell survival and promote healing at tissue injury sites.
The method improves tissue healing by sustaining cell viability and removing toxins, accelerating healing processes in challenging environments, as demonstrated by increased bone union and cell survival in animal models.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Background Art
[0001] Sites of tissue injury, disease, surgery, or trauma (such as those under surgical incisions and wounds, fractures, tendon and ligament ruptures, spinal fixation, joint reconstruction, trauma, fractures, or other physiological conditions that later require tissue healing) are acutely damaged by the initial trauma, disease, or injury, as well as surgical processes (such as periosteal stripping and the use of electrocautery). As a result, tissue damage caused by injury and surgery can have a significant negative impact on tissue healing. Furthermore, injury and surgery often target anatomical sites (such as within and around joints and intervertebral disc spaces) that are in a biological environment with immune privilege and insufficient angiogenesis, which further delays natural tissue healing. After surgery, it can take several weeks for angiogenesis and internal growth of tissue healing to occur, during which time a host environment that is not optimal for tissue survival persists.
[0002] Tissue healing at the site of tissue injury, disease, surgery, or trauma typically occurs through biological processes endogenous to the host organism, and such biological processes include the formation of a hematoma that causes infiltration of immune cells and ultimately generates robust angiogenesis via granulation tissue and callus. It can take several weeks for such endogenous processes to establish a biological environment that can consistently maintain tissue homeostasis. Exogenous contributions to healing are provided through interventions (such as surgery for fracture stabilization, reconstructive formation to supplement soft tissue defects, or transplantation of bone and cells by surgical transplantation or injection to provide additional biological assistance). A commonly used method for improving bone healing is, for example, surgical transplantation of autologous bone grafts to sites that require biological bone assistance. Transplanted cells have been shown to be intricately involved in contributing to the effectiveness of autologous bone grafts. However, the content rate of mesenchymal stem cells (cells important for the success of tissue healing) in autologous bone marrow aspirates or bone grafts obtained from long bones and iliac crests can be as low as 0.01% - 0.001%.
[0003] Poor handling of cell or bone grafts during surgery, and transplantation into atrophic / biologically inadequate host sites before endogenous biological support is fully established, can lead to stem cell loss and graft death, resulting in incomplete healing rates (as seen in cell-replenished orthopedic long bone and spine surgeries, as well as in other tissue healing and repair situations). This often leads to reduced graft survival rates, bone healing rates, and associated tissue repair rates.
[0004] In this field of technology, there is a need for methods and compositions that promote the healing, survival, and repair of cells in tissue injury sites, disease sites, surgical sites, wound sites, and / or other tissue defect sites, which can sustain tissue homeostasis until endogenous biological processes can play the same role. [Overview of the project]
[0005] This invention is based on the inventors' theory that the lack of local tissue homeostasis, resulting in insufficient cell viability and / or the absence of the ability to induce a regenerative phenotype, is one of the reasons for the incomplete healing rates observed in cell-replenished orthopedic long bone and spine surgery and other tissue healing situations.
[0006] In one embodiment, a nutrient support substance for assisting tissue survival is provided. This substance comprises a) a slow-release carrier for controlling nutrient release, and b) a nutrient cocktail containing glucose, wherein the slow-release carrier has a release half-life of 30 minutes to 14 days. In certain embodiments, the nutrient support substance is implantable or injectable. In certain embodiments, The nutrient cocktail includes commercially available powdered cell culture media (such as DMEM medium powder, EMEM medium powder, RPMI medium powder, IMDM medium powder, HAM F10 medium powder, or HAM F12 medium powder). In certain embodiments, the material is in the form of microparticles with a diameter of 1 micron to 5 mm. In certain embodiments, the carrier is a carrier polymer matrix, which is optionally PLGA.
[0007] In another embodiment, a method is provided for assisting tissue survival associated with injury, disease, or surgery. This method comprises administering a nutritional support substance described herein to a site of tissue injury, disease, surgery, or wound. In certain embodiments, the method further comprises administering a waste removal substance to a site of tissue injury, disease, surgery, or wound. In certain embodiments, the method comprises administering a nutritional support substance together with a bone graft, optionally in combination with a waste removal substance. In other embodiments, the method comprises administering a nutritional support substance together with cell therapy, optionally in combination with a waste removal substance.
[0008] In one embodiment, a method for increasing tissue healing at a site of tissue injury, disease, surgery, or wound includes introducing a nutritional support substance to the site of tissue injury, disease, surgery, or wound in need to improve tissue survival in the injured environment. In one embodiment, the substance is introduced during a surgical procedure, prior to the closure of the site of tissue injury, disease, or wound.
[0009] In another embodiment, a method for increasing tissue healing at a site of tissue injury, disease, surgery, or wound involves introducing a waste removal substance to the site of tissue injury, disease, surgery, or wound in which it is needed to improve cell survival in the injured environment. In one embodiment, the substance is introduced during a surgical procedure, prior to the closure of the site of tissue injury, disease, or wound.
[0010] In yet another embodiment, a method for increasing tissue healing at a site of tissue injury, disease, surgery, or wound includes introducing nutrient-supporting substances and waste-removing substances to the site of tissue injury, surgery, or wound in need to improve cell survival in the injured environment. In one embodiment, the substances are introduced during a surgical procedure, prior to the closure of the site of tissue injury, disease, or wound.
[0011] In yet another embodiment, a composition for increasing healing at a site of tissue damage, disease, surgery, or wound comprises an effective amount of a nutritional support substance in a physiologically acceptable delivery system suitable for delivery to the site of tissue damage, disease, surgery, or wound.
[0012] In yet another embodiment, a composition for increasing healing at a site of tissue damage, disease, surgery, or wound comprises an effective amount of a waste removal substance in a physiologically acceptable delivery system suitable for delivery to the site of tissue damage, disease, surgery, or wound.
[0013] In another embodiment, a composition for increasing healing at a site of tissue damage, disease, surgery, or wound comprises an effective amount of a nutritional support substance and a waste removal substance in a physiologically acceptable delivery system suitable for delivery to the site of tissue damage, disease, surgery, or wound.
[0014] Another embodiment is a composition for transplantation to a tissue injury site, disease site, surgical site, or wound site, wherein the composition is coated or impregnated with a nutritional support substance and / or waste removal substance capable of exerting its intended effect on the transplantation site.
[0015] Further other embodiments and advantages of these compositions and methods will be described in a later detailed description of their preferred embodiments. [Brief explanation of the drawing]
[0016] [Figure 1]This is an example of a method for preparing nutrient poly(lactic acid-co-glycolic acid) (PLGA) microparticles loaded with Dulbecco's Modified Eagle Medium (DMEM). A. A diagram showing the steps of formation of a primary emulsion, formation of a secondary emulsion by dropwise addition of the primary emulsion to 0.5% polyvinyl alcohol (PVA) under vortexing, and acquisition of cured microparticles by final washing. B. Sedimentation of cured microparticles by gravity after completion of the secondary emulsion step. C. Dark-field microscopy of microparticles at 40x magnification demonstrating that, in contrast to the white color of raw PLGA, DMEM powder changes color when encapsulated in PLGA spheres. [Figure 2] This experimental data demonstrates that essential nutrients are necessary for the cell survival of human bone marrow mesenchymal stem cells (hBM MSCs). Particles were prepared using PLGA loaded with Dulbecco's Modified Eagle Medium (DMEM) (a standardized cell culture medium nutrient composition). A. The survival rate of hBM MSCs was observed at each time point using buffered saline with and without nutrient particle supplementation. At 10 hours, light microscopy demonstrated that cells survived in a healthy state in the presence of nutrient particles (B), while cells almost completely died in the absence of particles (C). [Figure 3] This is an example of an in vitro test protocol comparing cell viability with and without the use of well inserts containing nutrient-releasing and / or waste-removing microparticles. [Figure 4] This is one embodiment of introducing nutritional support and / or waste removal substances (in this case, microparticles) to a tissue damage site or wound site for the purpose of improving tissue healing. [Figure 5] This graph shows the elution profile of DMEM-based wax-coated solid core microparticles exhibiting a sustained-release profile with a desirable initial burst release. [Figure 6]By using primary bone marrow-derived human mesenchymal stem cells (hBM-MSCs) as a model cell type, the in vitro viability of these cell types can be sustained using controlled-release nutrient microparticles. A synergistic effect was observed when fetal bovine serum (FBS) was used in combination with the culture medium. [Figure 7] While charcoal-based waste-removing microparticles showed minimal cell survival effects on their own, they demonstrated a synergistic effect in promoting cell viability in vitro when combined with controlled-release nutrient microparticles. [Figure 8] A differentiation assay of human bone marrow mesenchymal stem cells (hBM-MSCs) that survived for 3 weeks demonstrated that, when co-cultured with nutrient-eluting microparticles, stem cell pluripotency (adipogenic differentiation, chondrogenic differentiation, and osteogenic differentiation) was maintained to at least the same degree as hBM-MSCs (positive control) that survived with 10% fetal bovine serum (FBS). This suggests that nutrient supplementation may lead to improvement. For comparison, undifferentiated hBM-MSCs (negative control) demonstrated lower staining levels for differentiation markers. The upper panel shows qualitative monolayer staining with OilRed-O, Safranin-O, and Alizarin Red, respectively, performed to detect adipogenic differentiation, chondrogenic differentiation, and osteogenic differentiation. The lower panel shows quantified absorbance of retained stains. [Figure 9] These are radiographic images from a rat posterolateral lumbar fusion model demonstrating improved bone fusion at 8 weeks when nutrient microparticles were supplied along with an iliac bone autograft (A) compared to when blank particles were used (B). White arrows indicate the L4–L5 surgical level. [Modes for carrying out the invention]
[0017] The methods and compositions described herein introduce nutritional support and / or detoxification substances to injured sites, surgical sites, and / or other wound sites to improve local cell and tissue survival. It addresses this need in the art. Local nutritional supplementation and waste removal by direct transplantation or injection into the damaged or surgical site are novel approaches in supporting the viability and healing of injured tissues and can have a significant impact on future surgical procedures as well as other medical practice domains.
[0018] Such methods and compositions particularly offer potential for human use in surgeries to improve bone healing and soft tissue healing. In the field of orthopedic procedures, there is a direct and essential relevance between the research site and the clinical site, which particularly exists in spinal applications, reconstructive joint applications, and trauma applications. In such applications, surgeons often encounter tissue defects with lost vitality and face the difficulty of regenerating tissues under an inadequate biological environment. Since such methods and compositions focus on improving bone grafting and bone healing, they are essentially related to functional improvement, pain relief, and mobility restoration in spinal orthopedics, trauma orthopedics, and reconstructive orthopedics. The present invention has a wide range of potential uses, which include, but are not limited to, craniofacial reconstruction, fracture healing, spinal fixation, orthopedic soft tissue healing (tendons, muscles, ligaments, intervertebral discs), surgical wound healing, traumatic wound healing, and visceral organ healing. In addition to combined use with bone grafts, the compositions and methods of this technology are useful for combined use with micro-particle transplantation, injection, spraying, coating of grafts, mass transplantation, etc.
[0019] Such methods and compositions for stimulating tissue healing through nutrient supply and waste elimination dispense with biologically active drugs and molecules that, in some embodiments, may be harmful when used medically or surgically at non-physiological doses.
[0020] Therefore, in one aspect, as will be described in detail later, a composition is provided for increasing healing in such damaged, defective, or wounded sites when applied directly to a bone defect site, an injury site, or a wound site. In one aspect, the composition comprises an effective amount of a nutritional support substance in a physiologically acceptable delivery system suitable for direct delivery to the defect site, injury site, or wound site. In another aspect, the composition comprises an effective amount of a waste elimination substance in a physiologically acceptable delivery system suitable for direct delivery to the defect site, injury site, or wound site. In another aspect, the composition comprises an effective amount of a nutritional support substance and a waste elimination substance in a physiologically acceptable delivery system suitable for direct delivery to the defect site, injury site, or wound site.
[0021] In another aspect, as will be described in detail later, a method of increasing healing of a tissue defect, graft, injury, surgical site, or wound comprises introducing a nutritional support substance and / or a waste elimination substance to a tissue defect site, graft site, injury site, surgical site, or wound site to improve cell survival in the wound environment.
[0022] I. Components and Definitions Useful in Methods and Compositions A. Nutritional Provision and Nutritional Supplements Among physicians, it is considered that nutritional provision is very important in the repair, regeneration, and healing of damaged tissues. Appropriate nutritional provision by diet is known to improve tissue healing, and part of this is evidenced by the fact that in extensive trauma or burns, the body's daily calorie requirements can increase several-fold due to the resulting healing response. Further evidence exists in cases of renal or hepatic dysfunction or vascular disease, where electrolyte imbalances and inadequate tissue nutrient delivery lead to an inadequate associated wound healing response. The importance of cellular nutritional provision has penetrated into the medical and surgical fields, and among orthopedic surgeons, for example, fractures occurring in severely emaciated patients due to malignant tumors or end-stage multi-organ disease or starvation are considered essentially non-healing. Plastic surgeons often emphasize the importance of nutritional provision in the management of wounds and chronic ulcers. Amputation and limb Vascular surgeons managing patients with gangrene have shown that healing improves when the nutritional profile is optimized during surgery, indicating that nutritional status is a predictor of reduced surgical risk and improved prognosis.
[0023] The inventors have demonstrated that tissue healing also benefits from direct nutritional support to the affected area, regardless of whether it is a response to surgical intervention, injury, or disease. On the other hand, surgical or injured tissue layers consist of locally dehydrated tissue that cannot receive endogenous nutrient delivery from the host organism. Therefore, the methods and compositions described herein nourish injured tissue through a process of direct application / transplantation with the aim of improving healing outcomes across medical and surgical domains.
[0024] The “nutritional support substances” provided herein include “nutrient cocktails.” As used herein, “nutrient cocktail” means a composition comprising one or a mixture of several sugars, amino acids, vitamins, fatty acids, minerals, salts, and nucleic acids that maintain physiological pH. In certain embodiments, the nutrient cocktail comprises at least glucose. In certain embodiments, the nutrient cocktail comprises pH buffer salts, sodium and potassium salts, glucose, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cobalamin, vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, taurine, glucuronolacto It may contain carnitine, creatine, sodium pyruvate, adenine, adenosine, guanine, cytosine, thymine, uracil, dietary fatty acids (saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids with a length of 4 to 24 carbon atoms (such as palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentanoic acid, docosahexanoic acid, omega-3 fatty acids, and omega-6 fatty acids)), cholesterol, magnesium, potassium, calcium, boron, zinc, copper, iron, phosphorus, vanadium, strontium, silicon, selenium, nickel, or manganese. In another embodiment, the nutrient cocktail may contain all the essential amino acids, sugars, vitamins, nucleic acids, and buffer salts necessary for maintaining tissue homeostasis.
[0025] In another embodiment, the nutrient cocktail is derived from a cell culture medium preparation, and these include inorganic salts (CaCl2, Fe(NO3)3·9H2O, MgSO4, KCl, NaHCO3NaCl, NaH2PO4·H2O) and / or amino acids (L-arginine·HCl, L-cystine·2HCl, L-glutamine, glycine, L-histidine·HCl·H2O, L-isoleucine, L-leucine, L-lysine·HCl, L-methyl These include those found in the ATCC30-2002 formulation for Dulbecco's Modified Eagle Medium (DMEM), which contains thionine, l-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine·2Na·2H2O, L-valine, and / or vitamins (choline chloride, folic acid, myo-inositol nicotinamide, d-pantothenic acid, (hemicalcium)pyridoxine·HCl, riboflavin, thiamine·HCl, etc.). Further other components include d-glucose, phenol red, sodium salt, and sodium pyruvate. Other nutrients may include components from other known culture medium formulations (RPMI1640, EMEM, etc.) or components from other cell culture formulation derivatives of such culture medium formulations. Various mixtures of components from known cell culture media can be introduced into the nutrient mixture. On the other hand, well-known cell culture media are convenient mixtures, and these mixtures are known to be safe and effective for in vitro cell growth. This specification describes several commonly used cell culture media. These media are available in powdered form supplied by Fisher Scientific and other suppliers. Certain embodiments In this embodiment, the nutrient cocktail is provided as a powdered cell culture medium. In other embodiments, the nutrient cocktail is provided as a liquid or semi-solid cell culture medium.
[0026] Eagle's Minimal Essential Medium (EMEM) was one of the first widely used media, formulated by Harry Eagle from a simpler basal medium (BME). EMEM contains equilibrium salt solution, non-essential amino acids, and sodium pyruvate.
[0027] Dulbecco's Modified Eagle Medium (DMEM) contains nearly twice the concentration of amino acids and four times the amount of vitamins found in EMEM, as well as ferric nitrate, sodium pyruvate, and several co-amino acids. The initial formulation, containing 1,000 mg / L of glucose, was first reported for the culture of mouse embryonic cells. Further increasing the glucose to 4,500 mg / L has proven optimal for the culture of various cell types. DMEM is a basal medium and does not contain proteins or growth promoters. Therefore, supplementation is necessary to make DMEM a "complete" medium. DMEM is most commonly supplemented with 5-10% fetal bovine serum (FBS).
[0028] RPMI-1640 is a versatile culture medium with a wide range of applications for mammalian cells, particularly hematopoietic cells. RPMI-1640 was developed at the Roswell Park Memorial Institute (RPMI) in Buffalo, New York. It is a modified version of McCoy's 5A and was developed for the long-term culture of peripheral blood lymphocytes. RPMI-1640 differs from most mammalian cell culture media in that it uses a bicarbonate buffer system and its typical formulation pH is 8. RPMI-1640 supports the growth of a wide variety of cells growing as a monolayer in suspension.
[0029] Ham nutritional mixtures were initially developed to support the clonal proliferation of Chinese hamster ovary (CHO) cells. Many modifications have been made to the original formulation, including Ham F-12 medium (a more complex formulation than the original F-10, suitable for serum-free proliferation). Depending on the type of cells being cultured, the mixtures have been formulated for use with or without serum supplementation.
[0030] Ham F-10 has been shown to support the proliferation of human diploid cells (e.g., human fibroblasts and leukocytes) for chromosome analysis.
[0031] Ham F-12 has been shown to support the proliferation of primary rat hepatocytes and rat prostate epithelial cells. Ham F-12 supplemented with 25 mM HEPES provides more optimal buffering.
[0032] Coon's modification of Ham F-12: This medium contains nearly twice the amount of amino acids and pyruvate compared to F-12, and also includes ascorbic acid. This medium was developed for culturing hybrid cells generated by viral fusion.
[0033] DMEM / F12 is a mixture of DMEM and HAM F-12, a highly nutrient-rich complex medium. DMEM / F12 supports the growth of a wide range of cell types in both serum and serum-free formulations. To compensate for the loss of buffering capacity that occurs with serum-free formulations, a final concentration of 15 mM HEPES buffer is included in the formulation.
[0034] Iskov Modified Dulbecco's Medium (IMDM) is a highly nutrient-rich synthetic medium well-suited for high-density cell cultures with rapid growth. IMDM is a modified DMEM medium containing selenium and, compared to DMEM, includes additional amino acids, vitamins, and inorganic salts. IMDM contains potassium nitrate instead of ferric nitrate, and also contains HEPES and sodium pyruvate. IMDM was formulated for the proliferation of lymphocytes (e.g., the differentiation of monocytes into macrophages) and hybridomas.
[0035] B. Waste removal substances In addition to nutrient supply, waste removal is a complementary factor in maintaining cellular homeostasis in inadequate host environments. Charcoal, as one embodiment, is widely used in medical applications for drug detoxification and in scientific research for in vitro plant cell culture. There is considerable evidence that activated charcoal has a favorable effect on plant cell culture, which may be due to the adsorption of inhibitory compounds and sequesteration of toxic metabolites in the culture medium. On the other hand, charcoal has not been explored as an adjunct to animal cell culture or as a means of promoting in vivo cell / tissue survival for surgical applications. Previous studies have demonstrated that coated activated charcoal has the advantage of selectively adsorbing small molecules while having minimal effect on proteins and other large molecules. Activated charcoal has a high affinity for toxins and waste products normally excreted in urine, while having virtually no affinity for ions, thus avoiding undesirable adsorption of small charged nutrient particles and undesirable effects on local electrolyte balance. While dextran-coated charcoal microparticles are commercially available, dextran has been shown to induce interference with primary and secondary hemostasis, which would suggest its use is contraindicated in certain surgical applications due to the risk of bleeding. Instead, biocompatible coatings may help improve the practicality of waste removal materials in vivo. In one embodiment, these limitations could be overcome by using a cellulose coating to produce biocompatible coated charcoal, as it is assumed that cellulose not only does not hinder macromolecule adsorption by reducing the charcoal's porous profile, but also acts as a hemocoagulant, aiding in hemostasis. Therefore, activated carbon with a biocompatible cellulose coating is a useful waste removal material for the compositions or methods of the present invention.
[0036] In yet another embodiment, the waste removal substance is a flavonoid (such as those described in the Art). See, for example, Tremi, J and Smejkal, K, Flavonoids as Potent Scavengers of Hydroxyl Radicals, 2016 Comprehen. Rev., 15(4):820-8738 (incorporated herein by reference).
[0037] C. Delivery media suitable for direct delivery to tissue injury sites, disease sites, surgical sites, or wound sites. Another component of the nutrient support substance or waste removal substance is a delivery medium suitable for the release of the nutrient cocktail / waste removal substance. In one embodiment, the delivery medium is a suitable pharmaceutical additive, diluent, buffer, or carrier selected with respect to the intended administration route and standard pharmaceutical practices. In one embodiment, a carbonate buffer, or other physiologically useful and safe buffer that can be used to adjust the nutrient support substance and / or waste removal substance to a physiological pH for use in and around bone injury, defect, or disease conditions, is useful. In one embodiment, the carrier or buffer is adjusted to a pH of about 7.4.
[0038] The delivery of nutritional supplements and / or waste removal aids may be achieved in the form of solids for implantation, liquids for injection, powders, tips, pellets, microparticles, nanoparticles, capsules, creams, gels, lotions, pastes, coatings, impregnations of existing implants or tissues, combinations thereof, or impregnation devices containing the implanted nutritional / waste removal substance or any bioacceptable delivery device for the nutritional / waste removal substance. The composition may be administered topically alone (using saline or similar as a medium) or, in addition to various growth factors, scaffolds, extracellular matrix proteins, It may contain one or more types of delivery media selected from gelling agents and thickeners. For example, when administered topically with saline or similar, the nutrient / waste removal components can reach the entire bone marrow, whereas when a scaffold is used, such compositions can be localized to a given area of bone, improving only the bone material where needed.
[0039] In one embodiment, using microparticle aids to improve tissue healing and cell viability in surgical applications in humans is an alternative delivery mechanism. For example, introducing components essential for ensuring cellular homeostasis (specifically, nutrient supply and waste removal) via microparticles improves the osteogenic response, thereby improving bone healing and fusion rates in anatomical areas where such needs exist.
[0040] Various types of such microparticles are described in U.S. Patent No. 10,335,498 (incorporated herein by reference). In one embodiment, the delivery medium comprises cationic polymer microparticles, such as polyethyleneimine (PEI), chitosan, cyclodextrin, or dendrimers. In one embodiment, the delivery medium comprises a non-cationic polymer (e.g., dioleoylphosphatidylethanolamine (DOPE), cholesterol, polyamidoamine (PAMAM), or poloxamer). In one embodiment, a nutritional supplement and / or waste removal substance is complexed with a cationic polymer and encapsulated in microparticles (e.g., PLGA). When these particles are delivered to a bone defect site, injury site, or wound site, they can enter cells for tissue engineering applications. In one embodiment, PLGA particles are used to increase the encapsulation frequency, although complex formation with poly-L-lysine (PLL) can also increase encapsulation efficiency. Microparticles can also be prepared using other cationic substances (e.g., N-[1-(2,3-dioleoyloxy)propel]-N,N,N-trimethylammonium (DOTMA), 3-β-[N--(N,N'-dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), or cetyltrimethylammonium bromide (CTAB)). The encapsulation efficiency and nutrient elution profile can also be modified using polymer mixtures.
[0041] In one embodiment, the delivery medium is biologically inactive or has minimal biological activity. One embodiment includes inorganic microparticles (e.g., calcium phosphate or silica particles); polymers (but not limited to PLGA, polylactic acid (PLA), linear and / or branched PEI having different molecular weights (e.g., 2, 22, 25 kDa), dendrimers (PAMAM and polymethoacrylate, etc.)); lipids (but not limited to cationic liposomes, cationic emulsions, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), DOTMA, DMRIE, DOSPA) , containing distearoylphosphatidylcholine (DSPC), DOPE, or DC-chol); peptide-based vectors (but not limited to poly-L-lysine or protamine); or containing poly(beta-aminoester), chitosan, PEI-polyethylene glycol, PEI-mannose-dextrose, DOTAP-cholesterol, or PEI-PEG, PEI-PEG-mannose, dextran-PEI, OVA complex, PLGA microparticles, or PLGA microparticles coated with PAMAM.
[0042] In one embodiment, the delivery medium is a glycopolymer-based delivery medium (poly(glycomidomidoamine)(PGAA)) having the ability to complex with various polynucleotide types and form microparticles. These substances include methyl ester derivatives or lactone derivatives of various carbohydrates (D-glucarate(D), meso-galactarate(G), D-mannarate(M), and L-tartarate(T)). It is created by polymerization with a series of oligoethyleneamine monomers (containing 1 to 4 ethylenamines) (Liu and Reineke, 2006). A subset of these carbohydrates and four ethyleneamines in the polymer repeat unit produces excellent delivery efficiency.
[0043] In one embodiment, the delivery medium comprises a cationic lipid, such as DOTMA,2,3-dioleyloxy-N-[2-sperminecarboxamide]ethyl-N,N-dimethyl-1-propaneammonium trifluoroacetate (DOSPA,Lipofectamine); DOTAP; N-[1-(2,3-dimyristloxy)propyl](N-[1-(2,3-dimyristloxy)propyl]); N,N-dimethyl-N-(2-hydroxyethyl)ammonium bromide (DMRIE), DC-Chol; dioctadecylamideglycerylspermine (DOGS,Transfectam); or imethyldioctadeclyammonium bromide (DDAB). The positively charged hydrophilic head group of the cationic lipid typically consists of a monoamine group (such as tertiary and quaternary amines), a polyamine group, an amidinium group, or a guanidium group. A series of pyridinium lipids have been developed (Zhu et al., 2008, van der (Woude et al., 1997; Ilies et al., 2004). In addition to pyridinium cationic lipids, other types of heterocyclic head groups include imidazoles, piperidines, and amino acids. The main function of cationic head groups is to condense loaded nucleic acids through electrostatic interactions with slightly positively charged nanoparticles, thereby enhancing cellular uptake and endosomal extrusion.
[0044] Lipids having two linear fatty acid chains (such as DOTMA, DOTAP, and SAINT-2, or DODAC), as well as tetraalkyl lipid chain surfactants (dimers of N,N-dioleyl-N,N-dimethylammonium chloride (DODAC)) can be used as delivery media. All trans-oriented lipids have a hydrophobic chain length (C 16:1 , C 18:1 , and C 20:1 Regardless of the orientation, it may enhance transfection efficiency compared to its cis-oriented counterpart.
[0045] The structures of cationic polymers useful as delivery media include, but are not limited to, linear polymers (such as chitosan and linear poly(ethyleneimine)), branched polymers (such as branched poly(ethyleneimine) (PEI)), cyclic polymers (such as cyclodextrin), network (crosslinked) polymers (such as crosslinked poly(amino acids) (PAA)), and dendrimers. Dendrimers consist of a central core molecule from which several highly branched arms "grow" to form a tree-like structure in a symmetric or asymmetric manner. Examples of dendrimers include polyamidoamine (PAMAM) and polypropyleneimine (PPI) dendrimers.
[0046] DOPE and cholesterol are neutral copolymers commonly used to prepare cationic liposomes. Branched-chain PEI-cholesterol water-soluble lipopolymer complexes self-assemble to form cationic micelles. Pluronic (poloxamer) (nonionic polymer) and SP1017 (a combination of Pluronics L61 and Pluronics F127) can also be used.
[0047] In one embodiment, PLGA particles are used to increase encapsulation efficiency, but encapsulation efficiency can also be increased by forming a composite with PLL. Microparticles can also be prepared using other cationic substances (e.g., PEI, DOTMA, DC-Chol, or CTAB).
[0048] In one embodiment, no delivery medium is used; for example, the nutrient substance is used alone. Alternatively, it is used with a scaffold.
[0049] Examples of scaffold characteristics for use in the delivery of nutrient supplements / waste removal substances to bone defect sites, injury sites, or surgical sites include at least one of the following: biocompatibility, biodegradability, appropriate mechanical properties, and scaffold architecture. Biocompatible scaffolds or tissue engineering constructs do not induce immune responses, or if they do, the immune response is negligible. Biodegradable scaffolds allow for tissue regeneration at the graft site. Scaffolds have mechanical properties that are in harmony with the anatomical site of their implantation. For example, bone or cartilage scaffolds must have sufficient mechanical integrity to function from the time of implantation until the completion of the remodeling process. Scaffolds may have an interconnected pore structure and / or high porosity.
[0050] In the fabrication of scaffolds, three distinct groups of biomaterials (namely, ceramics, synthetic polymers, and natural polymers) are commonly used. While not generally used for soft tissue regeneration, ceramic scaffolds (such as hydroxyapatite (HA) and tricalcium phosphate (TCP)) are widely used for bone regeneration. Ceramic scaffolds are typically characterized by high mechanical rigidity, very low elasticity, and a hard, brittle surface. From a bone perspective, ceramic scaffolds exhibit excellent biocompatibility because they are chemically and structurally similar to the mineral phase of natural bone. Since ceramics are known to enhance the differentiation and proliferation of osteoblasts, the interaction between osteogenic cells and ceramics is important for bone regeneration.
[0051] As described above, many synthetic polymers are used, including polystyrene, poly-l-lactic acid (PLLA), polyglycolic acid (PGA), and poly-dl-lactic-co-glycolic acid (PLGA).
[0052] In another delivery medium embodiment, biological substances are used as scaffold biomaterials. Biological substances (such as collagen, various proteoglycans, alginate-based substrates, and chitosan) are all used to produce scaffolds for tissue engineering. Unlike synthetic polymer-based scaffolds, natural polymers are biologically active and typically promote superior cell adhesion and cell proliferation. Furthermore, natural polymers are also biodegradable, which therefore allows host cells to generate their own extracellular matrix over time.
[0053] Collagen and collagen-GAG(CG) scaffolds can be modified through physical and chemical crosslinking. Collagen-hydroxyapatite (CHA) scaffolds and collagen-hydroxyapitite (CHA) scaffolds may be useful for bone defects. Suitable biocompatible materials for polymers include, but are not limited to, polyacetic acid or polyglycolic acid and its derivatives, polyorthoesters, polyesters, polyurethanes, polyamino acids (such as polylysine), lactic acid / glycolic acid copolymers, polyanhydrides and ion exchange resins (such as sulfonated polytetrafluoroethylene), polydimethylsiloxanes (silicone rubber), or combinations thereof.
[0054] In one embodiment, the composite is embedded in or applied to a substance, such substance, but is not limited to, poloxamer, polyacrylamide, poly(2-hydroxyethyl methacrylate), carboxyvinyl polymer (e.g., Carbopol 934, Goodrich Chemical Co.), and cellulose derivatives (e.g., methylcellulose, acetic acid). This includes hydrogels of cellulose (and hydroxypropylcellulose), polyvinylpyrrolidone, or polyvinyl alcohol, or combinations thereof.
[0055] In some embodiments, the biocompatible polymer material is derived from a biodegradable polymer (such as collagen (e.g., hydroxylated collagen), fibrin, polylactic acid-polyglycolic acid, or polyacid anhydride). Other examples include, but are not limited to, any biocompatible polymer, whether hydrophilic, hydrophobic, or amphiphilic, such as ethylene vinyl acetate copolymer (EVA), polymethyl methacrylate, polyamide, polycarbonate, polyester, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polytetrafluoroethylene, N-isopropylacrylamide copolymer, poly(ethylene oxide) / poly(propylene oxide) block copolymer, poly(ethylene glycol) / poly(D,L-lactide-co-glycolide) block copolymer, polyglycolide, polylactide (PLLA or PDLA), poly(caprolactone) (PCL), or poly(dioxanone) (PPS).
[0056] In another embodiment, biocompatible materials include polyethylene terephalate, polytetrafluoroethylene, copolymers of polyethylene oxide and polypropylene oxide, combinations of polyglycolic acid and polyhydroxyalkanoates, gelatin, alginic acid, poly-3-hydroxybutyrate, poly-4-hydroxybutyrate, and polyhydroxyoctanoate, as well as polyacrylonitrile polyvinyl chloride.
[0057] In one embodiment, biocompatible materials for different polymers are derived from isolated extracellular matrix (ECM). ECM can be isolated from the endothelial layer of various cell populations, tissues, and / or organs, and can be isolated from any organ or tissue source, including, for example, the dermis of skin, liver, gastrointestinal tract, respiratory tract, intestinal tract, urinary tract, or reproductive tract of warm-blooded vertebrates. The ECM used in the present invention may be derived from a combination of sources. Isolated ECM can be prepared as sheets, particle form, gel form, and the like.
[0058] Biocompatible scaffold polymers may include silk, elastin, chitin, chitosan, poly(d-hydroxy acid), poly(anhydride), or poly(orthoester). More specifically, biocompatible polymers may include formed polyethylene glycol, poly(lactic acid), poly(glycolic acid), copolymers of lactic acid and glycolic acid, copolymers of lactic acid and glycolic acid with polyethylene glycol, poly(E-caprolactone), poly(3-hydroxybutyrate), poly(p-dioxanone), polypropylene fumarate, poly(orthoester), polyol / diketene acetal addition polymers, poly(sebacic acid anhydride) (PSA), poly(carboxybiscarboxyphenoxyphenoxyhexone) PCPP) may be poly[bis(p-carboxypheonoxy)methane] (PCPM), SA, CPP, and CPM copolymers, poly(amino acids), poly(pseudo-amino acids), polyphosphazene, derivatives of poly[(dichloro)phosphazene] or poly[(organo)phosphazene], polyhydroxybutanoic acid, or S-caproic acid, polylactide-co-glycolide, polylactic acid, polyethylene glycol, cellulose, oxidized cellulose, alginic acid, gelatin, or derivatives thereof.
[0059] Therefore, the polymer used as a scaffold may be formed from any of a wide range of materials, including polymers (including naturally occurring polymers, synthetic polymers, or combinations thereof). In one embodiment, the scaffold includes a biodegradable polymer. In one embodiment, a naturally occurring biodegradable polymer may be modified to yield a synthetic biodegradable polymer derived from a naturally occurring polymer. In one embodiment, the polymer is poly(lactic acid) ("PLA") or poly(lactic acid-co-glycolic acid) ("P LGA) In one embodiment, the scaffold polymer includes, but is not limited to, alginic acid, chitosan, poly(2-hydroxyethyl methacrylate), xyloglucan, copolymer of 2-methacryloyloxyethyl phosphorylcholine, poly(vinyl alcohol), silicone, hydrophobic and hydrophilic polyesters, poly(lactide-co-glycolide), N-isopropylacrylamide copolymer, poly(ethylene oxide) / poly(propylene oxide), polylactic acid, poly(orthoester), polyacryl anhydride, polyurethane, copolymer of 2-hydroxyethyl methacrylate and sodium methacrylate, phosphorylcholine, cyclodextrin, polysulfone and polyvinylpyrrolidine, starch, poly-D,L-lactic acid-para-dioxanone-polyethylene glycol block copolymer, polypropylene, poly(ethylene terephthalate), poly(tetrafluoroethylene), poly-epsilon-caprolactone, or crosslinked chitosan hydrogel.
[0060] In certain embodiments, a slow-release carrier is used as the nutrient support to control the release of the nutrient cocktail, resulting in a release half-life of approximately 30 minutes to 14 days (including the endpoint). In certain embodiments, the release half-life is 1 hour to 7 days. In other embodiments, the release half-life is 1 hour to 24 hours. In some embodiments, the release half-life is 1 day to 14 days. In some embodiments, the release half-life is 30 minutes to 10 hours. In some embodiments, the release half-life is approximately 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours. In other embodiments, the emission half-life is approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.
[0061] Slow-release carriers are typically prepared from membranes or matrices. Matrix-type formulations are prepared from either swellable hydrophilic polymers or non-swellable lipophilic pharmaceutical additives such as waxes and lipids. Polymers for use in slow-release systems are known in the art, and these polymers include those described herein, including poly-lactic acid-co-glycolic acid (PLGA), poly(lactic acid) (PLA), and poly(glycolic acid) (PGA). See du Toit LC, Choonara YE, Kumar P, Pillay V. Polymeric networks for controlled release of drugs: a patent review. Expert Opin Ther Pat. 2016 Jun;26(6):703-17. Epub 2016 Apr 27. This document is incorporated herein by reference. Currently, poly-lactic acid-co-glycolic acid (PLGA) is the best known and widely applied polymer in controlled-release systems. While these synthetic polymers have been highly successful due to their biocompatibility, biodegradability, and favorable release kinetics, they also face stability concerns for protein delivery. Poly-(glycolic acid) (PGA) and poly-(lactic acid) (PLA), along with the copolymer poly-(lactic acid-co-glycolic acid) (PLGA), are biodegradable synthetic polymers discovered in the 1960s as surgical sutures. The successful development of these polymers as surgical sutures led to their expanded use as polymeric biomaterials. Since then, these copolymers have been established as some of the most successful polymers widely studied for applications in controlled release systems and are considered the "gold standard" for biodegradable polymers for controlled delivery systems. PLGA is used for the release of a wide range of small molecule drugs, peptides, and proteins, including reproductive hormones, growth hormones, steroid hormones, anti-inflammatory drugs, cytokines, chemotherapeutic agents, antibiotics, narcotic antagonists, insulin, and vaccines. Compared to other polymers being studied for release control, PLGA is relatively easy to process into different device forms (such as injectable micro / nanospheres). See Daniel J, and David L Kaplan. “Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights.” Critical reviews in therapeutic drug carrier systems vol.30,3(2013):257-76. This document is incorporated herein by reference.
[0062] As used herein, the term "microparticles" refers to particles with a size of approximately 0.1 μm to approximately 5 mm, particles with a size of approximately 1 μm to approximately 100 μm, approximately 0.5 μm to approximately 50 μm, 0.5 μm to approximately 20 μm, particles with a size of approximately 1 μm to approximately 10 μm, particles with a size of approximately 5 μm, or mixtures thereof. All ranges include the endpoints and all integers between them.
[0063] As used herein, the term “nanoparticles” refers to particles with sizes of approximately 0.1 nm to approximately 1 μm, 1 nm to approximately 1 μm, approximately 10 nm to approximately 1 μm, approximately 50 nm to approximately 1 μm, approximately 100 nm to approximately 1 μm, approximately 250 nm to approximately 900 nm, or, favorably, approximately 600 nm to 800 nm. All ranges include the endpoints and all integers between them.
[0064] The substances commonly used as lipid carriers (prepared by various melting methods) are beeswax and carnauba wax. These waxes contain a wide range of chemicals (glycerides, fatty acids, fatty alcohols, and their esters, etc.). They are widely used as release retarders (coatings) in the design of sustained-release beads, tablets, suspensions, implants, and microcapsules. The advantages of waxes include good stability at various pH and moisture levels due to their non-swelling and water-insoluble properties, well-established safety in human applications, minimal impact on food in the gastrointestinal tract, and no over-release. In one embodiment, the carrier comprises at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or up to 100% carnauba wax or beeswax. See Shaki, Hossein & Ganji, Fariba & Vasheghani-Farahani, Ebrahim & Shojaosadati, Seyed. (2009). Sustained release of KCl from Beeswax / Carnauba wax microparticles. This document is incorporated herein by reference.
[0065] Using inexpensive yet safe biomaterials to embed waste removal substances and release nutrient supplements in a controlled manner addresses the high costs and safety concerns associated with other methods. Therefore, in vivo methods that directly apply nutrient supplements and waste removal substances to surgical repair sites, bone injury sites, wound sites, etc., significantly reduce treatment costs. Further information on other delivery media is available in U.S. Patent Application Publications (e.g., Nos. 2009 / 0155216 and 2019 / 0144856), as well as U.S. Patents 6,811,776 and 9,180,000, and other references disclosed herein.
[0066] In the embodiments described below, one embodiment of the delivery medium is poly(lactic acid-co-glycolic acid) (PLGA) polymer, which is the most widely used encapsulating agent for the production of drugs or factor-eluting biomaterials due to its favorable biocompatibility, biodegradability, and relative hydrophobicity that improves its in vivo lifespan. Furthermore, PLGA polymer is a U.S. Food and Drug Administration (FDA) It is approved for human use by the Pharmaceuticals Agency and the European Medicines Agency. Therefore, PLGA is predicted to be a preferred scaffolding material for providing nutrient elution by the method described herein. In one embodiment, PLGA particles are used to increase the encapsulation frequency, but complex formation with PLL can also increase encapsulation efficiency. Other cationic substances (e.g., PEI, DOTMA, DC-Chol, or CTAB) may also be used in the preparation of microparticles.
[0067] Other biocompatible materials include synthetic polymers in the form of hydrogels or other porous materials (e.g., permeable structures or forms) such as polyvinyl alcohol, polyvinylpyrrolidone and polyacrylamide, polyethylene oxide, and poly(2-hydroxyethyl methacrylate); natural polymers such as gum and starch; synthetic elastomers such as silicone rubber and polyurethane rubber; and natural rubber, as well as poly[.alpha.(4-aminobutyl)]-1-glycolic acid, polyethylene oxide (Roy et al., 2003), polyorthoesters (Heller et al., 2002), silk-elastin-like polymers (Megeld et al., 2002), and alginic acid (Wee et al. (al., 1998), EVAc (poly(ethylene-co-vinyl acetate), microspheres (poly(D,L-lactide-co-glycolide) copolymer and poly(L-lactide), poly(N-isopropylacrylamide)-b-poly(D,L-lactide), etc.), soy matrix (crosslinked with glyoxal and reinforced with bioactive fillers (e.g., hydroxyl apatite), etc.), poly(epsilon-caprolactone)-poly(ethylene glycol) copolymer, poly(acryloylhydroxyethyl) starch, polylysine-polyethylene glycol, agarose hydrogel, or lipid microtubule-hydrogel.
[0068] In one embodiment, the following polymers may be used: for example, natural polymers (starch, chitin, glycosaminoglycans (e.g., hyaluronic acid, dermatan sulfate, and chondrotin sulfate), as well as microbial polyesters (e.g., hydroxyalkanoates (copolymers of hydroxyvalerate and hydroxybutyrate), as well as synthetic polymers (e.g., poly(orthoesters) and polyacid anhydrides), and furthermore, homopolymers and copolymers of glycosides and lactides (e.g., poly(L-lactide, poly(L-lactide-co-D,L-lactide), poly(L-lactide-co-glycolide, polyglycolide and poly(D,L-lactide), poly(D,L-lactide-co-glycolide), poly(colysine lactate), and polycaprolactone).
[0069] The compositions of the present invention may also be for administration in biocompatible organic or inorganic matrices (including, but not limited to, collagen or fibrinogen matrices). Such matrices are assumed to act as carriers for the compositions in appropriate formulations or to contribute to promoting tissue healing by enhancing the effects of the compositions.
[0070] The delivery medium may also be a bone repair device or implant coated with nutrient substances (e.g., as microparticles contained within the carrier) and / or waste removal substances. Suitable devices and implants are described, in particular, in U.S. Patent Application Publications 2019 / 0209327 and 2019 / 0021862, which are incorporated herein by reference.
[0071] Once the nutritional supplement / waste removal substance has been prepared using an appropriate delivery medium (e.g., encapsulated in microparticles), application of the composition to the bone defect site, repair site, injury site, or surgical site may include any appropriate means. Such means may involve the graft and host tissue. Other surgical implantations, scaffolds, or injectables commonly used to improve the viability of both are directly surgically implanted, injected, or supplemented, or coated with other surgical implants, scaffolds, or injectables, or coated with or immersed in or sprayed with other surgical implants, scaffolds, or complexes of such substances with a delivery medium to a selected bone defect, injury, or repair site may be introduced by physical means (including, but not limited to, electroporation, sonoporation, magnetoporation, ultrasound, or needle injection).
[0072] "Encapsulation efficiency" (EE) is defined as the percentage of the target substance successfully captured within the microparticles during preparation. For example, the expected EE for PLGA microparticles is variable and can be highly dependent on the preparation method and the type of encapsulation material, but generally falls in the range of 30-90% according to prior literature using PLGA microspheres. See, for example, Han FY, Thurecht KJ, Whittaker AK, et al. 2016. Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Frontiers in Pharmacol., 7:185 (incorporated herein by reference). Depending on the delivery medium, the percentage of the active ingredient in the formulation may be high when the composition is used alone, or low when it is used as a coating (in which case most of the natural implants do not have nutritional or waste removal functions on their own).
[0073] In any case, the combination of the formulation and the delivery medium ensures sufficient capacity for nutrient delivery and waste removal in a reasonable volume to sustain tissue viability and healing for a period of at least one hour to a maximum of four weeks with a single administration of the composition. A desired duration of effect beyond four weeks can be achieved by repeatedly supplying the same or a different composition over a total treatment period determined by a person skilled in the art.
[0074] D. Tissue defect site, surgical site, repair site, wound site, or diseased site The term “site” where accelerated tissue healing is needed can be any number of areas containing tissue that is damaged, injured, eroded, brittle, or otherwise defective in a manner in which it is assumed that stimulating and promoting cell proliferation at that site would be beneficial. The stimulation and promotion of cell proliferation is assumed to accelerate tissue healing at that site compared to the rate of tissue healing observed in patients to whom the invention does not apply. Therefore, a site could be a bone injury site or other tissue injury site. Alternatively, a site could be a surgical intervention site. The term “injury site” includes bone fracture sites or soft tissue or organ injury sites. “Surgical intervention site” means that a site may be a surgical repair site involving the performance of a surgical incision or re-examination of an existing incision or open wound, as well as further interventions such as the insertion of a bone graft. A site may also be a combination of an injury site and a surgical intervention site. In other words, if a site is either an injury or a surgical intervention, this could be, for example, the placement of a graft at a fracture site. Another embodiment is a percutaneous intervention site that does not necessarily involve performing a surgical incision or re-examination of an existing incision or open wound, but relies on other minimally invasive means of performing injections and other forms of manipulation into the tissue toward the same objective of improving tissue healing, or by using a needle. Alternative embodiments of such sites that fall within the intended scope of the present invention will be readily apparent to those skilled in the art.
[0075] The site may be a site requiring bone healing or a site containing injured bone, eroded bone, or bone defect. Such embodiments may be in combination with each other, or in the injured site or outside. This can also be observed in combination with surgical intervention sites. Sites with injury and / or eroded bone may be more prone to injury (such as fragility fractures experienced by those with conditions like osteoporosis). Furthermore, in patients requiring bone fusion at a site, it can be anticipated that the site may also be the site of injury, and that injury may necessitate bone fusion. For example, spinal cord injury may require the fusion of two vertebrae to stabilize the spine. Alternatively, the site may be the site of another condition, such as degeneration or deformation between the vertebrae, which is then treated by surgically fixing the vertebrae.
[0076] The term “site containing tissue defect” refers to a site in which the tissue has a deficient composition or structure compared to healthy tissue. Such defects may be congenital or acquired through injury, surgery, disease, or other cases that would be well known to those skilled in the art. Sites with “tissue defect” or damaged tissue can be evaluated radiologically (e.g., by X-ray or computed tomography), as those skilled in the art would understand, or directly by surgical exposure and visualization. Thus, in a preferred embodiment of the present invention, the site may be an anatomical space between adjacent vertebrae that requires a bone graft or implant to fill a bone defect and enable spinal fixation. The present invention is considered particularly useful for spinal fixation where biologically inadequate sites are routinely created by the extensive use of extensive periosteal detachment and electrocautery.
[0077] The present invention is also considered useful for repairing tissues with minor damage, and therefore, it is possible to replenish the tissue layers that existed at the site before the injury or surgical intervention occurred. Such embodiments are considered particularly useful after the insertion of a graft into the bone, and it is thought that new bone formation will allow for more secure adhesion of the graft compared to what would be assumed in the absence of the effects of the present invention. One example is the internal growth of bone to the designed internal growth surface, which is found on many joint replacement grafts.
[0078] This invention may enable the regulation of bone healing to accelerate and improve the quality of healing. This is expected to allow for improved bonding speed and integration of fractures or graft fixation. In this clinical scenario, there is competition between fracture bonding / integration and graft failure, and this competition occurs particularly in defective bones exemplified by fragility fractures, pathological fractures, or atypical fractures, or fracture bonding failure. This invention is expected to promote bonding and integration, thereby reducing complications at the fracture or graft site and enabling faster patient mobilization.
[0079] In one embodiment of any aspect of the present invention, the surgical intervention may be an osteotomy. “Osteotomy” includes any surgical procedure that intentionally cuts a bone to alter its length, alignment, rotation, or position. The present invention is assumed to provide means by which the healing process can be accelerated after such a medical procedure.
[0080] In certain surgical procedures, bone grafts are used to accelerate bone growth and healing. It is hypothesized that applying the present invention in addition to bone grafts could further accelerate the bone healing process. One example of a situation where bone grafts may be used is when bone fusion is required. The present invention is thought to help not only accelerate healing at the site where bone is grafted, but also at the site where donor bone has been removed. Therefore, in one embodiment, the surgical intervention may involve extracting bone from a donor site for the bone graft. In another embodiment, the surgical intervention site may be the site of the bone graft itself. The promotion of bone formation is thought to be beneficial for bone repair and / or acceleration of bone formation at fracture sites. The promotion of fixation may also be useful in osseointegrated implants (e.g., teeth, fingers, facial prostheses, and hearing devices).
[0081] E. General elements As used herein, “patient,” “subject,” or “individual” means a mammalian animal, including humans, livestock or domestic animals, domesticated animals or pets, and animals typically used in clinical research. In one embodiment, the subject of such methods and compositions is a human. In one embodiment, the subject has tissue damage, tissue repair, or tissue disease.
[0082] "Medically acceptable pharmaceutical additives or carriers" means, but are not limited to, diluents, adjuvants, pharmaceutical additives, adjuvants, or media administered together with the active agent of the present invention. Medically acceptable carriers may be sterile liquids (such as water and oil) that are approved by a federal or state regulatory agency, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, more specifically for use in humans, and that are of petroleum, animal, plant, or synthetic origin (such as peanut oil, soybean oil, mineral oil, sesame oil, and similar). Water or aqueous saline and aqueous Dextrose and glycerol solutions are preferably used as carriers, specifically as injection solutions. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by EW Martin (Mack Publishing Co., Easton, PA), Gennaro, AR, Remington: The Science and Practice of Pharmacy (Lippincott, Williams and Wilkins), Liberman, et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, and Kibbe, et al., Eds., Handbook of Pharmaceutical Excipients, American Pharmaceutical Association, Washington.
[0083] As used herein, the term “treatment” means any method used to benefit a subject, i.e., to result in the reduction, delay of onset, reduction of severity, reduction of incidence, or prevention of one or more symptoms or aspects of the tissue damage, tissue repair, or tissue disease described herein. For the purposes of the present invention, treatment may be performed before, during, and / or after surgical treatment. In certain embodiments, treatment is performed after the subject has undergone surgery. In some embodiments, the term “to treat” includes suppressing, substantially preventing, the appearance of clinical or cosmetic symptoms of a condition, or reducing the severity and / or frequency of one or more symptoms resulting from tissue damage, surgery, repair, or disease.
[0084] "Effective dose" means the amount of a nutrient supplement and / or waste removal substance or any optional composition that is sufficient to provide a therapeutic benefit or therapeutic effect after an appropriate administration process. "Therapeutably effective dose" of a compound or pharmaceutical composition refers to the amount that is effective in quantitatively blocking, suppressing, treating, or reducing the symptoms of a particular disorder or disease. For example, "therapeutably effective dose" may refer to the amount of a nutrient supplement that is sufficient to rapidly or efficiently stimulate cell or tissue repair at the surgical site of the target compared to a similar untreated subject during surgery. It should be understood that the "effective dose" of a nutrient substance varies depending on the substance selected for use in the method, as well as the severity and extent of the tissue damage, wound, or disease. It should be understood that the "effective dose" of a waste removal substance varies depending on the substance selected for use in the method. Regarding dosage, it should be understood that, as is known in the art of individual nutrients, essential nutrient substances are, by definition, safe over a wide range of doses. Since the present invention concerns only local or regional tissue injury and not the whole organism, doses are generally not determined by body weight. If an injectable substance is used, the doctor or nurse will calculate the amount from the vial containing this amount. It can be injected by filling a container. In contrast, implants or scaffolds may include a fixed dosage form. While dose-setting studies using small molecules use mg / kg, those skilled in the art may also use other doses based on the teachings herein. In one embodiment, the effective amount of the nutrient composition delivered as microparticles or implants includes, but is not limited to, about 0.001 to about 500 mg / kg of body weight of the subject. In another embodiment, 100 micrograms to 50 grams can be injected into the subject in the delivery medium during and after surgery, and local injections can be repeated in volumes of 1 to 20 milliliters or 5 to 10 cc.
[0085] The terms "a" or "an" refer to one or more. For example, "an amino acid" will be understood to refer to one or more such amino acids. Thus, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.
[0086] As used herein, the term "approximately" means a variation of ±10% from a given reference value, unless otherwise specified.
[0087] The words “comprise,” “comprise,” and “comprise” are to be interpreted inclusively, not exclusively, that is, to include other ingredients or process steps not specifically mentioned. The terms “consist,” “consisting,” and their derivatives are to be interpreted in exclusively, not inclusively, that is, to exclude ingredients or steps not specifically mentioned.
[0088] The technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which the present invention pertains, and as those generally understood by reference to published texts (which provide general guidance to those skilled in the art for many of the terms used in this application). The definitions included herein are provided for the purpose of clarifying the descriptions of the components and compositions described herein and are not intended to limit the claimed invention.
[0089] II. Composition Accordingly, in one embodiment, a composition for increasing healing at a site of tissue injury or wound comprises an effective amount of a nutrient support and an optional effective amount of a waste removal substance in a physiologically acceptable delivery system suitable for delivery to a tissue defect, tissue injury, tissue disease, or surgical site. The composition may be formulated to suit the type of injury or surgical intervention in question. Suitable formulations will be obvious to those skilled in the art. Such suitable formulations may include, but are not limited to, solids for implantation, liquids for injection, powders, chips, pellets, microparticles, nanoparticles, capsules, creams, gels, lotions, pastes, coatings, impregnations of existing implants or tissues, and combinations thereof. The formulations may be conveniently present in unit dosage forms and may be prepared by any method well known in the field of pharmaceuticals. Such methods include the step of combining the active ingredient (the formulation of the present invention) with the suitable delivery medium described above. Generally, formulations are prepared by homogeneously and closely combining the active nutrient component (and other waste removal component) with a liquid carrier or a microsolid carrier or both, and then shaping the product as needed.
[0090] The formulations may include biocompatible, controlled-release preparations that are suitable for injection because they are liquid at low temperatures, but are expected to have gel characteristics at body temperature. “Low temperatures” means temperatures lower than typical healthy body temperature. Examples of such formulations, as will be well known to those skilled in the art, include those based on Pluronic Gel (Fl27) and ReGel®. Pluronic F127 is a cross-linked polyethylene glycol fibrino It is possible to combine it with the Gen complex, and it is assumed that the nutrients / waste removal substances combined with such a matrix will be optimally delivered to the desired active site.
[0091] The compositions of the present invention are intended for topical administration to sites where tissue healing or formation is required, when introduced into a suitable delivery medium. Such compositions may be used in the form of sterile aqueous solutions containing other substances (e.g., sufficient salt or glucose) to ensure isotonicity between the solution itself and the blood. The aqueous solutions should be appropriately buffered as needed (preferably to pH 3–9). In one embodiment, the pH of the formulation is approximately 7.4 for application to tissue injury / surgical sites. Preparation of suitable formulations under sterile conditions is readily achieved by standard pharmaceutical methods well known to those skilled in the art.
[0092] Formulations suitable for topical administration include aqueous and non-aqueous sterile injection solutions that may contain antioxidants, buffers, antibiotics, antifungals, antiparasitic agents, and other solutes that make the formulation isotonic with the intended recipient tissue, immunologically acceptable, and prophylactic against infection, as well as aqueous and non-aqueous sterile suspensions that may contain suspending agents and thickeners. The formulations may exist in unit or multi-dose microparticle quantities and may be stored in a freeze-dried state requiring only the addition of a sterile liquid carrier (e.g., ordinary saline for injection or implantation) immediately before use. Immediate injection solutions and suspensions may be prepared from the same sterile powders, granules, and tablets described above. See, for example, US2014 / 0056960. These formulations may then be prepared as microparticles or gels, or in other delivery systems disclosed herein.
[0093] In yet another embodiment, the composition for implantation at the surgical site is coated, mixed, or filled with a nutrient support substance or waste removal substance to be released after implantation at the tissue defect or injury site.
[0094] III. Method The present invention provides a method for increasing the healing of tissue damage or wounds, the method comprising introducing a nutrient support substance into a tissue repair site, a surgical site, or a wound site to improve cell survival in the wound environment. In one embodiment, the substance is introduced during the surgical procedure before closing the tissue repair site or wound site. In another embodiment, the substance is introduced into the tissue repair site or wound site before the surgical procedure, or without requiring the surgical procedure. In yet another embodiment, the substance is introduced into the tissue repair site or wound site after the closure of the tissue repair site or wound site, or after the surgical procedure.
[0095] As disclosed above, “substance” may include any nutritional support substance described herein, comprising one or more of sugars, amino acids, vitamins, fatty acids, minerals, salts, and nucleic acids, and / or cell culture media. The substance should maintain a physiological pH. In another embodiment, the method further comprises introducing a waste removal substance into a tissue repair site or wound site to sequester toxins that may negatively affect tissue healing or cell survival. The waste removal substance is one of the above and, in one embodiment, may include activated carbon. In another embodiment, the activated carbon is coated with cellulose. In another embodiment, one or more flavonoid compounds are included as the waste removal substance.
[0096] In one embodiment, the nutritional support substance is included in the delivery composition together with an optional waste removal substance. In an alternative embodiment, the nutritional support substance is included in one formulation or delivery medium, and the waste removal substance is included in another delivery medium. Such delivery mediums may be the same or different for those two types of compositions for delivery to tissue. Such delivery mediums are those described above, and such delivery mediums may include solids for implantation, liquids for injection, powders, chips, pellets, microparticles, nanoparticles, capsules, creams, gels, etc. This includes solutions, pastes, coatings, impregnations of existing implants or tissues, combinations thereof, or any biologically acceptable delivery device. In a particular embodiment, the delivery medium is microparticles composed of polymers (such as PLGA). Further other media may also be used.
[0097] According to one embodiment, the method comprises immersing, coating, layering, injecting, or spraying an effective amount of a nutrient support substance to a tissue injury or wound site, and applying an optional waste removal substance in the same manner. The site on which such application is performed may be a surgical field including a tissue defect site and related tissue type sites, such related tissue types include, but are not limited to, bone, periosteum, muscle, tendon, ligament, cartilage, fascia, vascular structures, granulation tissue, fat, and dermis. In another embodiment, the composition is introduced by inserting a delivery medium (such as those described herein) into the bone injury or wound site before surgical closure. In one embodiment, the delivery medium has the ability to deliver an effective amount of the nutrient support substance and an optional waste removal substance to the injury, repair, or regrowth site.
[0098] In yet another embodiment, the method includes injecting a nutrient composition or waste removal composition having the ability to deliver an effective amount of the support substance and an optional waste removal substance in vivo into a tissue injury site or wound site. The composition may include a liquid, gel, suspension, or matrix that can be delivered in this manner. In another embodiment, the injection of the composition may be performed after surgical closure at a time and dose selected by the surgeon and physician. In one embodiment, the injection is performed after surgical closure of a bone injury site or wound site.
[0099] The method may be applied before, during, and after any appropriate surgical procedure (including, among others, bone grafting, tissue repair, spinal fixation, or insertion of a graft into a bone defect, as described herein).
[0100] In the case of local administration, the administration is to any tissue cavity in which the formulation can improve tissue healing. This may be supplemented by an additional intervention at the same site. That is, this step may be performed to perform postoperative follow-up by injection or administration targeting the injured site or surgical repair site, after the local administration of a graft or other delivery medium to an area where support of tissue viability is needed during surgery. In yet another embodiment, nutrients and / or waste removal substances may be mixed and delivered together with the bone graft.
[0101] Other embodiments of the compositions and methods are also considered to fall within the scope of the skill of the art, based on the teachings provided herein. [Examples]
[0102] IV. Examples The following examples disclose specific embodiments of the methods and compositions described above and should be interpreted as encompassing any and all variations that become apparent as a result of the teachings provided herein. In these examples, Dulbecco's Modified Eagle Medium (DMEM) is a nutrient-rich cell culture medium. PLGA combined with DMEM provides a reliable example of a component for generating nutrient microparticles.
[0103] Example 1: Development of nutrient-eluting microparticles and waste-removing microparticles to sustain cell viability. As described below, the inventors have developed a process for generating nutrient-eluting microparticles. Microparticle characterization, including measurement of encapsulation efficiency (EE), elution profile, and microscopic analysis, is performed as part of the basic characterization. The optional synergistic use of charcoal-based waste removal microparticles along with nutrient delivery enhances cell lifespan. Life can be improved.
[0104] A. Preparation of PLGA-loaded nutrient microparticles: The solid-in-oil-in-water method is used. Briefly, the primary emulsion is a homogeneous suspension of nutrient solids in a bath of dissolved polymer. When the primary emulsion is directly added to a surfactant (e.g., PVA; polyvinyl alcohol), then spherical droplets of nearly uniform size and shape are obtained due to hydrophilic-hydrophobic interactions between the primary emulsion and the water bath in the presence of the surfactant. This final mixture (known as the secondary emulsion) is capable of forming microparticles, and it is also possible to induce particle hardening by gradually extracting the organic solvent from the droplets. Finally, PLGA particles remain in a suspended surfactant solution, which can be removed by gravity separation.
[0105] Figures 1A-1C show an example of a stepwise preparation protocol using dark-field microscopy. Chloroform is used for the primary emulsion, and 0.5% PVA is used as a surfactant for the secondary emulsion. Under a chemical fume hood at room temperature, the DMEM fine powder is suspended in 10 × w / v chloroform containing an equal weight of dissolved PLGA, and then sonicated in a bath for 10 seconds. This forms a solid-in-oil primary emulsion.
[0106] The primary emulsion is added dropwise to a test tube containing deionized water with an excess of 1% w / v polyvinyl alcohol while vortexing at medium speed. This solid-in-oil-in-water secondary emulsion is then gently stirred at 200 rpm for 3 hours using a magnetic stirrer until the microparticles have fully cured. The excess supernatant is decanted, and the remaining microparticles are transferred to a small glass scintillation vial and washed three times with ice-cold deionized water, allowing the particles to settle in between washes. After centrifugation at 1000 g for 5 minutes, the final wash solution is discarded. The microparticles are stored at -80°C until freeze-dried to produce the final microparticles.
[0107] B. Preparation of charcoal microparticles: Waste removal microparticles are generated using cellulose-coated activated carbon. Park TJ, et al. 2008. Heparin-cellulose-charcoal composites for drug Detoxification prepared using room temperature ionic liquids. Chem. Commun.: 5022-5024: Cellulose-coated charcoal microparticles are generated using a solid-in-water ionic liquid method with 1-butyl-3-methylimidazolium chloride ([BmIm][Cl]) as the solvent in the primary emulsification. Cellulose is added to [BmIm][Cl] and heated at 70°C for 30 minutes to completely dissolve it. Uncoated activated carbon beads of size 50-150 μm are added to this solution by stirring, and this primary emulsion is added dropwise to an ethanol bath and stirred for 24 hours. The beads are washed with redistilled water for 3 hours, dried in a desiccator, and stored in an aqueous manner.
[0108] C. Characterization of nutrient microparticles: Using the described protocol, microparticles with a diameter of 50–300 microns can be easily generated. The consistency of generation can be confirmed by measuring the size of the microparticles using dark-field microscopy immediately after generation (Figures 1A–1C).
[0109] D. Encapsulation Efficiency (EE): EE is measured by chemically extracting a pre-measured amount of nutrient microparticles. This extraction is performed by dissolving the particles in chloroform and then vigorously extracting them with deionized water. DMEM content is measured using phenol red ( The absorbance spectrophotometric method is used, with the components of the DMEM medium (as an indicator of DMEM content) being used. After alkaneization with concentrated sodium hydroxide, the peak absorbance at 560 nm is measured. 23 A serially diluted solution of water containing DMEM of known concentration is used as a standard, and the EE is calculated from this reference.
[0110] Example 2: Microparticles sustain cell viability and maintain their regenerative phenotype in vitro. To demonstrate whether these microparticles adequately support cell viability and can maintain stem cell pluripotency, viability assays are necessary. Using human mesenchymal stem cell lines, it is possible to demonstrate whether nutrient-eluting microparticles or waste-removing microparticles (or both) are sufficient to sustain cell viability in vitro. To demonstrate the maintenance of a regenerative phenotype, the ability of surviving cells to differentiate over time into the osteogenic, chondrogenic, and adipogenic pathways can be evaluated.
[0111] To this end, co-culture experiments using human mesenchymal stem cell lines will be conducted to demonstrate the ability of microparticles to maintain and sustain cell viability for up to 21 days. Then, cell pluripotency will be assessed at multiple time intervals to demonstrate the persistence of pluripotency. The success of the co-culture assay will indicate that the nutrient and / or waste removal microparticles are sufficient to maintain the regenerative phenotype and cellular vitality of the cells.
[0112] Primary human bone marrow mesenchymal stem cells (hBM MSCs) were cultured, and a preliminary cell viability assay was performed (Figures 2A-2C). Performing the viability assay establishes the effectiveness of microparticles in enhancing cell viability in multiple cell types. hMSC cell lines offer the additional advantage of allowing cell collection at various time intervals to evaluate the maintenance of their pluripotent phenotype. Cells were provided in either 1× HEPES-buffered saline (HBSS) alone or 1× HBSS + microparticles (0.65 mg microparticles per 1000 cells). Cells were stained with trypan blue, and viability was calculated at multiple time points up to 60 hours. A dramatic difference in cell viability was observed between these two conditions. This assay demonstrates that nutrient supply is necessary for the viability of hBM MSCs.
[0113] Example 3: Wax-coated slow-release nutrient particles Solid core slow-release nutrient microparticles were achieved by generating microparticles using a DMEM-based nutrient composition with a dry coating method using 95% to 100% carnauba wax. Solid DMEM particles were initially generated by adding a low dose of an antibiotic-antifungal mixture of penicillin, streptomycin, and amphotericin to inhibit undesirable bacterial growth. This was carried out by vigorously mechanically stirring the solid DMEM particles with or without weighted beads as a mechanical catalyst until the particles were completely coated with carnauba wax powder.
[0114] To demonstrate cell viability up to 4 weeks, a fixed amount of 20,000 cells containing nutrient microspheres, biocompatible charcoal particles, or a combination of both, is added to individual wells of a 12-well culture plate (Figure 3). The ratio of microparticles to cells is gradually increased to 0.5 mg, 2 mg, and 5 mg per 1000 cells to optimize the microparticle concentration. The culture medium is HEPES-buffered saline with or without fetal bovine serum (ThermoFisher, Waltham, MA), with a control well containing only blank PLGA particles. Cell viability and proliferation trends are revealed by collecting cells in a triple series at 0, 8, and 24 hours, and then every few days thereafter, up to day 25. To separate the microparticles from the cell culture monolayer, a Transwell insert (Corning, Cornin) is used under 5% CO2. Using g,NY), co-culture experiments will be conducted using tissue culture plates. This will allow for easy imaging of the monolayer without light interference from microparticles.
[0115] The nutrient elution of microparticles generated using this method showed a logarithmic profile with a half-life of approximately 20 hours and a desirable initial burst release (Figure 5).
[0116] Using these wax-coated microparticles, in vitro viability tests were conducted using monolayer human bone marrow-derived mesenchymal stem cells as a model cell type. Cells were cultured in physiological saline with nutrient microparticles or without nutrient microparticles. Physiological saline containing 2% and 10% fetal bovine serum (FBS) was used as a positive control. The synergistic effect of adding 1% serum to nutrient microparticles was also tested. Cell culture viability tests over three weeks demonstrated that strong viability was obtained in response to nutrient microparticles alone, and that the addition of just 1% serum produced not only an additive effect but also a synergistic effect (Figure 6). The addition of activated carbon microparticles demonstrated an additional synergistic effect, suggesting that waste removal plays a role in improving cell viability (Figure 7). To confirm that the phenotype was not lost, the pluripotency of cells that survived for three weeks was checked (Figure 8). The overall results suggest that nutrient microparticles have a positive in vivo effect, providing sustained support to cells, and that they work synergistically with extracellular fluid (which contains nutrients similar to those found in natural serum).
[0117] To test the in vivo efficacy of these wax-coated nutrient microparticles in sustaining tissue survival, clinically mimicked animal studies were conducted. Nutrient microparticles were used to test the ability to maintain bone graft survival in a rat model of lumbar fusion. In this model, autologous iliac bone grafts were harvested from the pelvis of animals undergoing surgery. These bone grafts were mixed with either blank microparticles (containing wax only; control group) or an equal amount of wax-coated nutrient microparticles (experimental group). Lumbar fusion was then performed by exposing the transverse processes at the L4 and L5 levels of the lumbar vertebrae, removing the protrusions from the host bone surface, and placing the microparticle-bone graft mixture in the host site. Radioactive healing was compared by X-ray analysis. The results of this analysis demonstrated a significant increase in bone formation in animals supplemented with nutrient microparticles compared to the control group (Figure 9).
[0118] These experimental examples demonstrate our hypothesis that graft viability is improved by supplementing the fundamental factors necessary for maintaining cellular homeostasis in the immediate post-operative site, thereby improving the rate of tissue healing. Specifically, before soft callus formation occurs after bone destruction, the graft is deprived of a reliable endogenous blood supply and simultaneously suffers from localized tissue inflammation. 7 Therefore, nutrient supplementation and sequestering of cellular waste products (such as in the form of locally supplied microparticles) sustain the ability of cells to survive in host environments where such supplementation and sequestering would otherwise be unfavorable.
[0119] All patents, patent applications, and publications (including websites) cited herein are incorporated herein by reference. While the present invention has been described with reference to specific embodiments, it will be understood that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
[0120] Specific Embodiments 1. A nutritional support substance for assisting tissue survival, wherein the nutritional support substance is a) A slow-eluting carrier for controlling nutrient release, b) A nutrient cocktail containing glucose, Includes, The slow-release carrier has a release half-life of 30 minutes to 14 days, and the nutrient support substance is the same.
[0121] 2. The nutritional support substance according to Embodiment 1, wherein the nutritional support substance is transplantable or injectable.
[0122] 3. The nutritional support substance according to Embodiment 1 or Embodiment 2, wherein the nutrient cocktail comprises DMEM medium powder, EMEM medium powder, RPMI medium powder, IMDM medium powder, Ham F10 medium powder, or Ham F12 medium powder.
[0123] 4. The nutritional support substance according to any one of Embodiments 1 to 3, wherein the substance is in the form of microparticles with a diameter of 1 micron to 5 mm.
[0124] 5. The nutritional support substance according to any one of Embodiments 1 to 4, wherein the carrier is a carrier polymer matrix and optionally PLGA.
[0125] 6. The nutritional support substance according to any one of Embodiments 1 to 3, wherein the carrier is a coating.
[0126] 7. The nutritional support substance according to Embodiment 6, wherein the coating comprises at least 95% wax or wax-like substance.
[0127] 8. The nutritional support material according to any one of Embodiments 1 to 7, wherein the material is in a form impregnated into a porous graft.
[0128] 9. The nutritional support substance according to any one of Embodiments 1 to 7, wherein the substance is in the form of chips, spheres, or blocks measuring 2 cm to 20 cm in size.
[0129] 10. The nutritional support substance according to any one of Embodiments 1 to 7, wherein the substance is in the form of nanoparticles measuring 5 nanometers to 1 micron.
[0130] 11. A nutritional support substance according to any one of Embodiments 1 to 10, further comprising an antibiotic and / or antifungal agent to inhibit the growth of undesirable contamination.
[0131] 12. A method for assisting tissue survival in connection with injury, disease, or surgery, wherein the method comprises administering a nutritional support substance described in any one of Embodiments 1 to 11 to a site of tissue injury, disease, surgery, or wound.
[0132] 13. A method for supplying autologous bone graft chips, wherein the method comprises administering a nutritional support substance described in any one of Embodiments 1 to 11 together with the bone graft.
[0133] 13. A method for assisting cell therapy, wherein the method comprises administering a nutritional support substance described in any one of Embodiments 1 to 11 together with cell therapy.
[0134] 14. A method for increasing the healing of tissue damage, disease, surgery, or wound, wherein the method comprises introducing a nutrient support substance described in any of Embodiments 1 to 11 into a site of tissue damage, disease, surgery, or wound in order to improve cell survival in the wound environment.
[0135] 15. The method according to Embodiment 14, wherein the substance is introduced during a surgical procedure before closing the site of tissue damage, disease, surgery, or wound.
[0136] 16. The method according to Embodiment 14, wherein the substance is introduced into the site of tissue damage, disease, surgery, or wound before a surgical procedure.
[0137] 17. The method according to Embodiment 14, wherein the substance is introduced into the tissue injury site, disease site, surgical site, or wound site after the closure of the tissue injury site, disease site, surgical site, or wound site, or after the surgical procedure.
[0138] 18. The method according to Embodiment 14, wherein the substance is introduced into the site of tissue damage or wound without surgical intervention.
[0139] 19. The method according to any one of Embodiments 14 to 18, wherein the nutritional support substance comprises a mixture of one or more sugars, amino acids, vitamins, fatty acids, minerals, salts, and nucleic acids, and a cell culture medium, and has a physiological pH.
[0140] 20. The method according to any one of Embodiments 14 to 19, further comprising introducing a waste removal substance into the tissue damage site, disease site, surgical site, or wound site in order to remove toxins from the tissue damage site, disease site, surgical site, or wound site.
[0141] 21. The method according to Embodiment 20, wherein the waste removal substance includes activated carbon.
[0142] 22. The method according to any one of Embodiments 14 to 21, wherein the nutrient support substance is optionally included in the delivery composition together with the waste removal substance.
[0143] 23. The method according to Embodiment 22, wherein the delivery composition is a solid for implantation, a liquid for injection, a powder, a chip, a pellet, microparticles, nanoparticles, a capsule, a cream, a gel, a lotion, a paste, a coating, an impregnation of an existing implant or tissue, a combination thereof, or any biologically acceptable delivery device.
[0144] 24. The method according to Embodiment 23, wherein the microparticles are composed of one or more PLGA or other encapsulation polymers.
[0145] 25. The method according to any one of Embodiments 14 to 24, wherein the introduction step comprises one or more of immersing, coating, layering, injecting, impregnating, or spraying an effective amount of the supporting substance together with an optional waste removal substance onto the tissue injury site, disease site, surgical site, or wound site.
[0146] 26. The method according to any one of Embodiments 14 to 24, wherein the introduction step comprises inserting a delivery composition having the ability to deliver an effective amount of the support material and an optional waste removal material in vivo into the site of tissue damage, disease, surgery, or wound before surgical closure.
[0147] 27. The method according to any one of Embodiments 14 to 24, wherein the introduction step comprises injecting a delivery composition having the ability to deliver an effective amount of the support substance and an optional waste removal substance in vivo into the site of tissue damage, disease, surgery, or wound.
[0148] 28. The method according to Embodiment 24, wherein the injection is performed before, during, or after surgical closure of the tissue injury site or wound site, or without surgical intervention.
[0149] 29. The method according to any one of embodiments 14 to 25, wherein the surgical procedure is bone grafting, tissue repair, spinal fixation, or insertion of a graft into a bone defect.
[0150] 30. A composition for increasing healing at a site of tissue damage, disease, surgery, or wound, wherein the composition comprises an effective amount of a nutrient support substance and an optional effective amount of a waste removal substance in a physiologically acceptable delivery system.
[0151] 31. A composition for implantation into a tissue damage site, disease site, surgical site, or wound site, coated with a nutrient support substance or a waste removal substance.
[0152] References 1.Gould SE,et al.2000.Cellular contribution of bone graft to fusion.J.Orthoped.Res.,18:920-927. 2.Kruyt MC,et al.2004.Osteogenicity of autologous bone transplants in the goat.Transplantation 77:504-509. 3.Holton J,et al.2016.The Basic Science of Bone Marrow Aspirate Concentrate in Chondral Injuries.Orthopedic reviews 8:6659. 4.Hernigou P,et al.2005.Percutaneous autologous bone marrow grafting for nonunions.Influence of the number and concentration of progenitor cells.J.Bone Joint Surg.Amer.,87:1430-1437. 5.Tuchman A,et al.2017.Autograft versus Allograft for Cervical Spinal Fusion:A Systematic Review.Global Spine J.,7:59-70. 6.Sen MK,Miclau T.2007.Autologous iliac crest bone graft:should it still be the gold standard for treating nonunions? Injury 38 Suppl 1:S75-80. 7.Marsell R,Einhorn TA.2011.The biology of fracture healing.Injury 42:551-555. 8.Han FY,Thurecht KJ,Whittaker AK,et al.2016.Bioerodable PLGA-Based Microparticles for Producing Sustained-Release Drug Formulations and Strategies for Improving Drug Loading.Frontiers in Pharmacol.,7:185. 9.Allahyari M,Mohit E.2016.Peptide / protein vaccine delivery system based on PLGA particles.Human vaccines & Immunotherapeutics,12:806-828. 10.Yao T,Asayama Y.2017.Animal-cell culture media:History,characteristics,and current issues.Reproduc.Med.and Biol.,16:99-117. 11.Derlet RW,Albertson TE.1986.Activated charcoal--past,present and future.Western J.Medicine 145:493-496. 12.Sandeman SR,et al.2017.A haemocompatible and scalable nanoporous adsorbent monolith synthesised using a novel lignin binder route to augment the adsorption of poorly removed uraemic toxins in haemodialysis.Biomed.Materials 12:035001. 13.Pan M,Staden Jv.1998.The use of Charcoal in in vitro culture-A review.Plant Growth Reg.26:155-163. 14.Thomas TD.2008.The role of activated charcoal in plant tissue culture.Biotech.Adv.,26:618-631. 15.Park T,et al.2011.Biocompatible charcoal composites prepared by ionic liquids for drug detoxification.Macromolecular Research 19:734-738. 16.Winchester J.1983.Hemoperfusion.In:Drukker W,Parsons F,Maher J editors.Replacement of Renal Function by Dialysis:A textbook of dialysis,2 ed.Netherlands:Springer 17.Zeerleder S,et al.2002.Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests.Thrombosis research 105:441-446. 18.Agostino D.1976.The effect of high molecular dextran on coagulation and metastases.Tumori 62:245-254. 19.Keshavarzi S,et al.2013.Clinical experience with the surgical family of absorbable hemostats(oxidized regenerated cellulose)in neurosurgical applications:a review.Wounds:a compendium of clinical research and practice 25:160-167. 20.McCall RL,Sirianni RW.2013.PLGA nanoparticles formed by single-or double emulsion with vitamin E-TPGS.J.Visualized Exp.51015. 21.Mu L,Feng SS.2003.A novel controlled release formulation for the anticancer drug paclitaxel(Taxol):PLGA nanoparticles containing vitamin E TPGS.J.Controlled Release,86:33-48. 22.Park TJ,et al.2008.Heparin-cellulose-charcoal composites for drug detoxification prepared using room temperature ionic liquids.Chem.Commun.:5022-5024. 23.Held P.2018.Using phenol red to assess pH in tissue culture media.BioTek Live Cell Imaging Application Note. 24.Shive MS,Anderson JM.1997.Biodegradation and biocompatibility of PLA and PLGA microspheres.Adv.Drug Deliv.Rev.28:5-24. 25.Yano,K.et al,2015 Fate,origin,and roles of cells within free bone grafts.,J.Orthop.Sci,20:390-396 26.Bibby,SRS and JPG Urban,2004.Effect of nutrient deprivation on the viability of intervertebral disc cells,Eur Spine J.13:695-701 27.Panse N,,et al.Diet,wound healing and plastic surgery.Indian J Plast Surg.2013 Jan;46(1):161-3. 28.Maroz N,Simman R.Wound Healing in Patients With Impaired Kidney Function.J Am Coll Clin Wound Spec.2013 Apr;5(1):2-7.29.Karalis M,et al.Effect of experimentally induced liver cirrhosis on wound healing of the post-extraction tooth socket in rats.Eur Surg Res.2008;40(2):190-6. 30.Cordero-Espinoza L,Huch M.The balancing act of the liver:tissue regeneration versus fibrosis.J Clin Invest.2018 Jan 2;128(1):85-96. 31.Kueper J,et al.Evidence for the adverse effect of starvation on bone quality:a review of the literature.Int J Endocrinol.2015;2015:628740. 32.Meesters DM,et al.Malnutrition and Fracture Healing:Are Specific Deficiencies in Amino Acids Important in Nonunion Development? Nutrients.2018 Oct 31;10(11).33.Medical Advisory S.Management of chronic pressure ulcers:an evidence-based analysis.Ont Health Technol Assess Ser.2009;9(3):1-203. 34.Bauer JD,et al.The effectiveness of a specialised oral nutrition supplement on outcomes in patients with chronic wounds:a pragmatic randomised study.J Hum Nutr Diet.2013 Oct;26(5):452-8. 35.Brown SA,et al.Oral nutritional supplementation accelerates skin wound healing:a randomized,placebo-controlled,double-arm,crossover study.Plast Reconstr Surg.2004 Jul;114(1):237-44. 36.Stojanovic MD,et al.Enhanced Recovery after Vascular Surgery.Front Med(Lausanne).2018;5:2. 37.Jabbour J,et al.Role of nutritional indices in predicting outcomes of vascular surgery.J Vasc Surg.2019 Aug;70(2):569-79 e4. 38.Rahm D.A guide to perioperative nutrition.Aesthet Surg J.2004 Jul-Aug;24(4):385-90. 39.Singh,M et al.2000,Jan.Cationic microparticles:A potent delivery system for DNA vaccines.Proc.Natl Acad Sci.USA 97(2):811-816.
Claims
1. a) a slow dissolution carrier for controlling nutrient release; b) a nutrient cocktail containing glucose; A nutritional support material for supporting tissue survival comprising: The nutritional support material, wherein the slow eluting carrier has a release half-life of 30 minutes to 14 days.
2. The nutritional support material of claim 1 , wherein the nutritional support material is implantable or injectable.
3. The nutritional support material of claim 1 or claim 2, wherein the nutrient cocktail comprises a media powder.
4. The nutritional support material of claim 3, wherein the nutrient cocktail comprises DMEM medium powder, EMEM medium powder, RPMI medium powder, IMDM medium powder, Ham's F10 medium powder or Ham's F12 medium powder.
5. The nutritional support substance of claim 1, wherein the nutrient cocktail comprises glycine, alanine, arginine, asparagine, aspartic acid, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, proline, serine, threonine, valine, folic acid, calcium, magnesium or potassium.
6. A nutritional support material according to any one of claims 1 to 5, wherein the material is in the form of microparticles having a diameter of from 1 micron to 5 mm.
7. The nutritional support material of any one of claims 1 to 6, wherein the carrier is a carrier polymer matrix, optionally PLGA.
8. The nutritional support material of any one of claims 1 to 6, wherein the carrier is a coating.
9. 9. The nutritional support material of claim 8, wherein the coating comprises at least 95% wax or wax-like material.
10. The nutritional support material of any one of claims 1 to 9, wherein the material is in the form of a porous implant impregnated therein.
11. A nutritional support material according to any one of claims 1 to 9, wherein the material is in the form of chips, spheres or blocks having a size of between 2cm and 20cm.
12. A nutritional support material according to any one of claims 1 to 9, wherein the material is in the form of nanoparticles of between 5 nanometers and 1 micron.
13. 13. The nutritional support material of any one of claims 1 to 12, further comprising an antibiotic and / or an antifungal agent to inhibit the growth of undesirable contaminants.
14. A nutritional support material as described in any one of claims 1 to 13 for use in a method of supporting tissue survival associated with injury, disease or surgery, said method comprising administering the nutritional support material as described in any one of claims 1 to 13 to a site of tissue injury, disease, surgery or wound.
15. A nutritional support material as described in any one of claims 1 to 13 for use in a method for replenishing autograft bone chips, said method comprising administering the nutritional support material as described in any one of claims 1 to 13 together with a bone graft.
16. A nutritional support material described in any one of claims 1 to 13 for use in a method for supporting cell therapy, the method comprising administering a nutritional support material described in any one of claims 1 to 13 together with cell therapy.
17. A nutritional support material as described in any one of claims 1 to 13 for use in a method for increasing healing of tissue injury, disease, surgery or wounds, the method comprising introducing the nutritional support material as described in any one of claims 1 to 13 to a site of tissue injury, disease, surgery or wound to improve cell survival in the wound environment.
18. 20. The nutritional support material of claim 17, wherein the material is introduced during a surgical procedure prior to closure of the site of tissue injury, disease, surgery or wound.
19. 20. The nutritional support material of claim 17, wherein the material is introduced to the site of tissue damage, disease, surgery or wound prior to a surgical procedure.
20. The nutritional support material of claim 17, wherein the material is introduced to the site of tissue damage, disease, surgery or wound following closure of the site of tissue damage, disease, surgery or wound following a surgical procedure.
21. 20. The nutritional support material of claim 17, wherein the material is introduced to the site of tissue damage or wound without surgical intervention.
22. The nutritional support material of any one of claims 17 to 21, wherein the nutritional support material comprises a mixture of one or more of sugars, amino acids, vitamins, fatty acids, minerals, salts and nucleic acids, and cell culture medium, and has a physiological pH.
23. 23. The nutritional support material of any one of claims 17 to 22, wherein the method further comprises introducing a waste removal material to the site of tissue damage, disease, surgery or wound to remove toxins from the site of tissue damage, disease, surgery or wound.
24. 24. The nutritional support material of claim 23, wherein the waste removal material comprises activated charcoal.
25. The nutritional support material of any one of claims 17 to 24, wherein the nutritional support material is optionally included in a delivery composition together with the waste removal material.
26. 26. The nutritional support material of claim 25, wherein the delivery composition is a solid for implantation, a liquid for injection, a powder, a chip, a pellet, a microparticle, a nanoparticle, a capsule, a cream, a gel, a lotion, a paste, a coating, an impregnation of an existing implant or tissue, a combination thereof, or any biologically acceptable delivery device.
27. 27. The nutritional support material of claim 26, wherein the microparticles are composed of one or more of PLGA or other encapsulating polymers.
28. 28. The nutritional support material of any one of claims 17 to 27, wherein the introducing step comprises one or more of soaking, coating, layering, injecting, impregnating or spraying an effective amount of the support material, along with optional waste removal substances, onto the site of tissue damage, disease, surgery or wound.
29. 28. The nutritional support material of any one of claims 17 to 27, wherein the introducing step comprises inserting a delivery composition capable of delivering an effective amount of the support material and optional waste removal material in vivo into the site of tissue damage, disease, surgery or wound prior to surgical closure.
30. 28. The nutritional support material of any one of claims 17 to 27, wherein the introducing step comprises injecting a delivery composition capable of delivering an effective amount of the support material and optional waste removal material in vivo at the site of tissue damage, disease, surgery or wound.
31. 28. The nutritional support material of claim 27, wherein said injecting is performed before, during or after surgical closure of the tissue injury or wound site, or is performed without surgical intervention.
32. The nutritional support material of any one of claims 17 to 28, wherein the surgical procedure is bone grafting, tissue repair, spinal fusion or insertion of an implant into a bone defect.
33. A composition for increasing healing at a site of tissue damage, disease, surgery or wound, said composition comprising an effective amount of a nutritional support substance and optionally an effective amount of a waste removal substance in a physiologically acceptable delivery system.
34. A composition for implantation at a site of tissue damage, disease, surgery or wound that is coated with a nutritional support or waste removal substance.
